Nejat Duzgunes Ph.D. (State University of New York at Buffalo)
Professor, University of the Pacific, Ssan Francisco, San Francisco, CA · United States
Editorial leadership for Journal of Advanced Pharmaceutical Science And Technology ISSN 2328-0182
Research interests
- Dna
- Cancer Biology
- Nanobiotechnology
- Virology
- Biophysics
- Cancer Research
- Microbiology
- Nanoparticles
- Hiv
- Cells
Biography
Dr. Nejat Duzgunes, PhD, is a Professor at the University of the Pacific in San Francisco, CA, United States. He earned his doctoral degree from the State University of New York at Buffalo. Dr. Duzgunes has contributed significantly to the field of infectious disease therapeutics, with his most-cited work, "Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier" (2021), garnering 51 citations and reflecting his research focus on alternative antimicrobial strategies. He has an established publication record with over 22 indexed articles, demonstrating sustained scholarly productivity in his areas of expertise.
Selected publications
- Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier 2021 cited 51×
- Recent Strategies for Cancer Therapy: Polymer Nanoparticles Carrying Medicinally Important Phytochemicals and Their Cellular Targets 2023 cited 36×
- Inhibition of Viral Membrane Fusion by Peptides and Approaches to Peptide Design 2021 cited 35×
- Photocytotoxicity of Liposomal Zinc Phthalocyanine in Oral Squamous Cell Carcinoma and Pharyngeal Carcinoma Cells 2020 cited 11×
- Photodynamic Therapy of Oral Cancer and Novel Liposomal Photosensitizers 2023 cited 9×
- Liposome-Encapsulated Antibiotics for the Therapy of Mycobacterial Infections Recent 2025 cited 6×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JAPST for your work?
This journal is guided by Nejat Duzgunes (Professor, University of the Pacific, Ssan Francisco, San Francisco, CA) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.